Source:http://linkedlifedata.com/resource/pubmed/id/15953676
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1-2
|
pubmed:dateCreated |
2005-8-24
|
pubmed:abstractText |
The induction of tumor protective immunity against neuroblastoma remains a major challenge for active immunotherapy. Fractalkine is a unique Th1 CX3C chemokine known to induce adhesion and migration of leukocytes mediated by both, a membrane-bound and soluble form, respectively. Here, we tested the hypothesis that chemokine gene therapy with fractalkine (FKN) induces an effective anti-neuroblastoma immune response amplified by targeted IL-2 using the anti-GD2 antibody ch14.18 fused with IL-2 (ch14.18-IL-2). For this purpose, NXS2 cells were genetically engineered to stably produce murine FKN (NXS2-FKN). Transcription and expression of the mFKN gene in tumor tissue of mice inoculated with NXS2-FKN cells were demonstrated in vivo. Importantly, mFKN exhibited a reduction in primary tumor growth and spontaneous liver metastases in syngenic A/J mice. This effect was boosted by targeted IL-2 using small non-curative doses of ch14-18-IL-2. The amplification of the FKN induced immune response was specific, since a non-specific antibody-IL-2 fusion protein ch225-IL-2 was ineffective. In summary, we demonstrated for the first time that chemokine gene therapy is amplified by targeted IL-2 suggesting a combination of both strategies as an adjuvant therapy for neuroblastoma.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/CX3CL1 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Chemokine CX3CL1,
http://linkedlifedata.com/resource/pubmed/chemical/Chemokines, CX3C,
http://linkedlifedata.com/resource/pubmed/chemical/Cx3cl1 protein, mouse,
http://linkedlifedata.com/resource/pubmed/chemical/DNA Primers,
http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-2,
http://linkedlifedata.com/resource/pubmed/chemical/Membrane Proteins
|
pubmed:status |
MEDLINE
|
pubmed:month |
Oct
|
pubmed:issn |
0304-3835
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
18
|
pubmed:volume |
228
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
187-93
|
pubmed:dateRevised |
2007-11-15
|
pubmed:meshHeading |
pubmed-meshheading:15953676-Animals,
pubmed-meshheading:15953676-Base Sequence,
pubmed-meshheading:15953676-Chemokine CX3CL1,
pubmed-meshheading:15953676-Chemokines, CX3C,
pubmed-meshheading:15953676-DNA Primers,
pubmed-meshheading:15953676-Gene Therapy,
pubmed-meshheading:15953676-Gene Transfer Techniques,
pubmed-meshheading:15953676-Humans,
pubmed-meshheading:15953676-Interleukin-2,
pubmed-meshheading:15953676-Liver Neoplasms,
pubmed-meshheading:15953676-Membrane Proteins,
pubmed-meshheading:15953676-Mice,
pubmed-meshheading:15953676-Neuroblastoma
|
pubmed:year |
2005
|
pubmed:articleTitle |
Fractalkine gene therapy for neuroblastoma is more effective in combination with targeted IL-2.
|
pubmed:affiliation |
Charite Children's Hospital, Campus Virchow, Humboldt University, Augustenburger Platz 1, 13353 Berlin, Germany.
|
pubmed:publicationType |
Journal Article,
Review,
Research Support, Non-U.S. Gov't
|